MOLECULAR partners

Extending the Boundaries of Targeted Cancer Therapies

Patrick Amstutz, CEO

January 2026



Disclaimer

This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as "aim", "anticipate", "expect", "guidance", "intend", "outlook", "plan", "potential", "will" and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include, but are not limited to, those set forth in under the heading "Risk Factors" in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at www.molecularpartners.com. In addition, this presentation contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Molecular Partners' audited consolidated financial statements at and for the year ended December 31, 2025 are not yet available. As a result, the financial information described in this presentation is preliminary and unaudited, represents management's estimate as of the date hereof and is subject to completion of the Company's financial closing procedures for the fourth quarter and fiscal year ended December 31, 2025. This preliminary financial information may materially differ from the actual results that will be reflected in the Company's audited consolidated financial statements when such financial statements are completed and publicly disclosed. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the Company's preliminary results.

Any forward-looking statements speak only as of the date of this presentation and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Extending the Boundaries of Targeted Cancer Therapies

DARPin
Designed Ankyrin Repeat Protein



Our Company

- Clinical-stage biotech company, founded 2004
- Operations & listing in Switzerland (SIX, 2014) and US (Nasdaq, 2021)
- Financed (USD ~116 M / CHF ~93 M*) to capture upcoming value inflection points

Our Capabilities

- **DARPin therapeutics**: new class of drugs, clinically-validated, proprietary platforms
- Strong team to execute up to clinical POC
- Global partnerships to access technology & capabilities (Orano Med)

Our Pipeline

- Differentiated **Assets** with focus in **Oncology**
- **MP0712 / Targeted radiotherapy** and **MP0533 / next-gen immune cell engagers**
- Early clinical readouts for patient value across indications with high unmet need

*Unaudited financials as of December 31, 2025.
POC, proof of concept.

Continued Innovation in DARPin Discovery, Therapeutic Designs

DARPin Drug Design Process

Proprietary DARPin Libraries

- Powered by >20 years of clinical learnings
- Designed for low immunogenicity



Differentiated Candidates

Radio-DARPin therapeutics



Conditional, logic-gated Switch-DARPin candidates



Multispecific DARPin candidates

Tailored to Patient Needs



Targeted DARPin Therapeutics

- ✓ Highly precise tumor targeting
- ✓ Tumor-localized activity
- ✓ Low uptake in healthy tissues

Our Pipeline – Differentiated Therapeutics for Patient Value

PLATFORM	CANDIDATE	RESEARCH	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Radio-DARPin Therapy (RDT)	**MP0712**	**SCLC & NECs** *^{212}Pb x DLL3*		oranomed *Co-development**		
	MP0726	**Ovarian Cancer** *^{212}Pb x MSLN*	oranomed *Co-development**			
	Undisclosed Programs (Solid Tumors)	**Radio - C**				
		Radio - D				
		Radio - E				
		Radio - F				
Next-Gen Immune Cell Engagers	MP0317	**Advanced Solid Tumors** *FAP x CD40*				
	MP0533	**r/r AML and AML/MDS** *CD33 x CD123 x CD70 x CD3*				
	Switch-DARPin T Cell Engager	*CD3 x CD2 x MSLN x EpCAM*				
	MP0621 (Switch-DARPin)	**HSCT** *cKit x CD16a x CD47*				

*The co-development agreement with Orano Med includes up to 10 targeted radiotherapy programs, including MP0712 and MP0726.
AML, acute myeloid leukemia; DLL3, Delta-like ligand 3; HSCT, hematopoietic stem cell transplant; MDS, myelodysplastic syndrome; MSLN, mesothelin; NEC, neuroendocrine cancer; r/r, relapsed/refractory; SCLC, small cell lung cancer.

MOLECULAR partners

Radio-DARPins

- Ideal vectors for precise delivery of potent radio-isotopes
- Potential to unlock broad target space across solid tumor indications



Radio-DARPins for Next-Gen Targeted Alpha Therapy

DARPin: IDEAL VECTOR FOR RADIOPHARMACEUTICALS

- Proven selective targeting
- High affinity, tumor retention
- Broad target space
- Small size



ALPHA-EMITTING THERAPEUTIC ISOTOPE

- Proven clinical efficacy
- High energy deposition

SURFACE ENGINEERING

- Enabled by high stability
- Reduce kidney accumulation

HALF-LIFE EXTENDER

- Tailored systemic exposure
- Promote tumor uptake

Global Partnership to Develop ^{212}Pb Radio-DARPin Therapeutics

Combining DARPin versatility with the power of ^{212}Pb for next-gen Targeted Alpha Therapy

MOLECULAR PARTNERS
PIONEERS of DARPin THERAPEUTICS

ORANO MED
PIONEERS of TARGETED ALPHA THERAPY

FULL VALUE CHAIN PARTNERSHIP

World class technologies & capabilities combined

INDIANA, US:
Industrial scale manufacturing
Global shipping hub
ATLab US

TEXAS, US:
Preclinical development
GMP supply for early clinical phases

SWITZERLAND:
Preclinical assessment
DARPin engine, fast & high throughput

FRANCE:
^{212}Pb starting material
ATLab Europe

Pipeline of ten ^{212}Pb radiotherapy products

1	^{212}Pb x DLL3	**MP0712**
2	^{212}Pb x MSLN	**MP0726**
3		
4		
5		
6		
7		
8		
9		
10		

4 Radio-DARPin programs
50:50 cost and share split

2 MP-owned programs
with opt-in option for OM for
50:50 cost:share split

4 MP-owned programs

Our Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics

Ken Herrmann, M.D.
Chair

James Cook
Member

Jason Lewis, Ph.D.
Member

Michael Morris
Member

- Chaired by Prof. Ken Herrmann, M.D., globally renowned expert in the field of nuclear medicine
- Other Board members bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development

MOLECULAR partners

MP0712

Targeted Radiotherapy for Lung Cancer

- Specific tumor uptake reported in initial human images
- Phase 1/2a in US open, early data in 2026



MP0712: Why DLL3-Targeting Radiotherapy for SCLC



Radiotherapy (MP0712)

- Phase 0/1
- SCLC highly radio-sensitive
- Manageable side effects
- Combinable with other MoAs

T Cell Engagers

- Tarlatamab approved
- 40% RR
- 9.7 months DoR
- Substantial side effects

Antibody-Drug Conjugates

- Phase 1/2
- 70% RR
- Risk of chemo-resistance
- Manageable side effects

DoR, duration of response; MoA, mode of action; RR, response rate; SCLC, small cell lung cancer.

MP0712: Potent Efficacy at Clinically-Relevant Dose in Mice

High Tumor Accumulation
(Tumor > Kidney)



Reduction of Established Tumors



Steiner et al, TRP 2024
Croset et al, EANM 2024
Lizak et al, SNMMI 2024

Mice xenografted i.v. with NCI-H82. Dose: 10 µCi of ^{212}Pb at 0.01 mg/kg of DLL3 DARPin. Efficacy study in NCI-H82 s.c. model / MP0712 and negative control injected 4 x 10 µCi at 0.01 mg/kg or 8 x 5 µCi at 0.01mg/kg every 1; 10 µCi = 370 kBq

Targeting DLL3: Why do we see High Tumor Uptake, Despite the low Copy Number

High Tumor Accumulation
(MP0712: Tumor > Kidney)





?

Low DLL3 Density on Tumor Cells
(of <1000 receptors/cell)







Croset et al, EANM 2024
Lizak et al, SNMMI 2024

NCI-H82 i.v. model: ^{212}Pb-DOTAM-DARPin - single injection - dose: 10 µCi (0.01 mg/kg). SCLC, small cell lunc cancer.

MP0712-DLL3 DARPin is Rapidly Internalized and Accumulates Intracellularly in DLL3-expressing Cells *in vitro*



Surface-bound DLL3-DARPin is rapidly internalized into SHP-77 human SCLC cells*



Internalized DLL3-DARPin shows significant co-localization to the endosomal compartment in hDLL3-HEK cells**



DLL3-DARPin accumulates in hDLL3-HEK cells over time (beyond the bound fraction at saturation)*

* Internalization of DARPins labelled with anti-DARPin Fab-Alexa 488 conjugate
** Immunofluorescence co-staining of anti-DARPin antibody, an early endosomal marker (EEA1) and cell nucleus marker (DAPI) after (3 h incubation)
MFI, Mean Fluorescence Intensity.

Hypothesis: Free Surface DLL3 is Continually Replenished for Binding and Internalization of MP0712



MP0712 – format selection:
Optimized half-life and DARPin binder to exploit internalization & replenishment of DLL3 for radio-payload accumulation in SCLC cells

MP0712 Development Pathway

1. Imaging



2. Treatment



Named Patient Access Program:

- Imaging and dosimetry with ^{203}Pb
- Option for treatment with ^{212}Pb

*Request from NuMeRI, Pretoria, South Africa**

Phase 1/2a Study:

- Safety of **^{212}Pb**
- Efficacy signals
- Includes an imaging and dosimetry step with ^{203}Pb

NuMeRI, Nuclear Medicine Research Infrastructure; SCLC, small cell lung cancer; SPECT, single-photon emission computed tomography.

SPECT/CT Imaging of ^{203}Pb-MP0712 in SCLC: A Case Example from a Named Patient Access Program in South Africa

Patient characteristics

- 69-year-old male (smoker)
- Small cell neuroendocrine carcinoma of the lung
- Stage III at referral, primary tumor located at superior mediastinum

Treatment history

- Radiotherapy and chemotherapy

Dosing & Result

- 5.1 mCi of ^{203}Pb-MP0712
- Stage IV by MP0712 - SPECT with 4 liver mets



➢ **Initial high blood pool, followed by specific uptake in primary and metastatic lesions over time, and limited accumulation in healthy organs in line with MP0712 MoA**

Patient imaged as part of a Named Patient Access Program at NuMeRI, Pretoria, South Africa.
Example of patient case series presented with courtesy of Prof. Dr. M. Sathekge.
Full data are planned to be presented by the NuMeRI team at the Theranostics World Congress (TWC) 2026.

MP0712 Phase 1/2a Study for SCLC and other NECs

- First-in-Human, US multicenter, Phase 1/2a study of MP0712 monotherapy
- Patients with small cell lung cancer (SCLC) and other neuro-endocrine cancers (NECs)
  - Every patient will be imaged (^{203}Pb) before treatment (^{212}Pb)
  - Patient pre-selection on DLL3 expression: not planned for SCLC and LC NEC of lung, foreseen for epNEC

Phase 1: Dose Escalation
Main objectives: safety, RP2D
N=15–39 patients SCLC and lung LC NEC; N=9-39 patients epNEC

Phase 2a: Dose Expansion and PoC
Main objectives: efficacy signals, confirm safety and RP2D
N=30 patients SCLC and NEC



* Evaluable patients (Bayesian Logistic Regression Model guided dose escalation)

**epNEC to start at a dose level previously tested in SCLC or LC NEC of lung at which a first signal of pharmacological activity is detected. RP2D for epNEC is anticipated to be same as RP2D for SCLC/LC NEC of lung.

IO, immuno-oncology; LC NEC, large cell neuroendocrine cancer; PoC, proof-of-concept; RP2D, recommended phase 2 dose.

MP0712 Conclusions & Outlook



MP0712: ^{212}Pb x DLL3 Radio-DARPin therapeutic candidate for SCLC

- Strong pre-clinical data with attractive BioD, efficacy & safety profile
- High tumor uptake leveraging rapid internalization & replenishment of DLL3
- Initial human images* show specific uptake in primary & metastatic tumor lesions supporting intended MoA

Outlook

- Full ^{203}Pb-MP0712 compassionate care imaging & dosimetry data at TWC in January 2026
- MP0712 Phase 1 open in US, first patient first dose expected in Q1'26
- Initial data from Phase 1 in 2026

*Patient case from Named Patient Access / Compassionate care in South Africa, imaged with ^{203}Pb-MP0712.
BioD, biodistribution; HLE, half-life extension; SCLC, small cell lung cancer; TWC, Theranostics World Congress.

MOLECULAR partners

MP0726

Targeted Radiotherapy for Ovarian Cancer

- Targeting membrane-bound MSLN
- Progressing to FIH imaging



^{212}Pb x MSLN Targeted Radio-DARPin for Ovarian Cancer (OC)

Combining distinctive DARPin features with the power of ^{212}Pb for next-gen targeted alpha therapy

OC: high medical need and marginal progress

- > 50% patients die within 5 years post-diagnosis (diagnosis often in late stage)
- Poor treatment options: ~80% recurrence rate post 1L chemo, limited 2L options (FRα-targeted Tx relevant for only 40% patients)

MSLN: a promising target for OC as 1st indication

- Highly expressed in OC (>80% prevalence), expression maintained in metastases
- Shed MSLN detected in serum of OC patients, might limit efficacy of MSLN-targeted therapies[1,2,3,4] (e.g., CAR T/NK, ADC, TCE in development)

RDT x MSLN: targeted delivery of alpha radiation with ^{212}Pb

- MSLN DARPin targets **membrane-proximal epitope** (and not shed MSLN)
- ^{212}Pb payload: high energy alpha emissions in short time frame
- Potential for combinations with immunotherapy (incl. next-gen TCEs)

Product composition



1. Awuah et al. 2016; 2. Zhang et al. 2011; 3. Smith et al. 2024 (ASCO poster); 4. Pastan et al. 2024.
ADC, anti-drug conjugate; CAR T, chimeric antigen receptor T cell; FRα, folate receptor alpha; MSLN, mesothelin; NK, natural killer cell; OC, ovarian cancer; TCE, T cell engager; Tx, treatment.

MP0726: ^{212}Pb x MSLN Radio-DARPin for Ovarian Cancer

Cell binding maintained despite shed MSLN



Favorable biodistribution

in hMSLN-MC38 tumor model



Outlook: Progressing MP0726 to FIH imaging

Wullschleger S, et al., AACR 2025.

OVCAR-8 Cell binding competition assay (100nM DARPin with increasing concentration of shed MSLN). Mice xenografted s.c. with hMSLN-MC38 (Biocytogen). Dose: 10 µCi of ^{212}Pb at 0.01 mg/kg of MSLN DARPin. FIH, first in human.

Outlook & Conclusions – Radio-DARPin Therapeutics

Radio-DARPin Therapeutics



MP0712	**DLL3 x ^{212}Pb** SCLC & NECs	*Overcome low target density on tumor cell*
MP0726	**MSLN x ^{212}Pb** Ovarian Cancer	*Selectivity for membrane-bound antigen*

Ongoing projects
Nominate 1–2 for FIH imaging mid 2026

Radio C	*Overcome low target density on tumor cell*
Radio D	*Exquisitely low kidney uptake*
Radio E	*Address high homology to receptors on healthy tissues*
Radio F	…

Next projects
Preparation of building blocks for research focus in 2027

- **Targets A+B**
- **Targets A+C**
- **Targets B+C**
- **Target E**

Multi-specifics to address tumor heterogeneity

FIH, first in human; NEC, neuroendocrine cancer; SCLC, small cell lung cancer.



Outlook

Outlook and Upcoming Milestones in 2026

MP0712	• **First-in-Human Phase 1 study open in US, first patient dosing imminent** • Full imaging and dosimetry data from South Africa presentation at TWC in January 2026 • Initial safety data from Phase 1 anticipated in H1 2026, initial activity in H2 2026
Radio-DARPin Therapy (RDT)	• Progress **MP0726 towards FIH imaging** • Nomination of new RDT programs mid 2026
MP0533	• Conclusion of dose escalation, update in H1 2026 • **Investigator-initiated combo trials** under discussion
Switch-DARPin	• **Lead candidate selection** in H1 2026, update at AACR 2026
MP0317	• **Phase 2 combo study started** in France, now dosing patients

Cash USD ~116 M (CHF ~93 M*, incl. short-term time deposits) ensures funding until 2028

*Unaudited financials as per December 31, 2025.
FIH, first in human; TWC, Theranostics World Conference.

MOLECULAR partners

Twenty Years of Pioneering
DARPin Therapeutics for Patients

Thank You



Our Team, Summer 2025



MOLECULAR partners

MP0317

A FAP-localized CD40 agonist for local immune cell activation and TME modulation

- Phase 2 combo IIT ongoing in advanced biliary tract cancer

MP0317: Unlocking CD40 Activity Through Local Activation

Problem: Toxicity of CD40 antibodies has so far limited their activity



- **CD40 agonists** can activate **B cells, DCs and MΦ** to enhance the efficacy of IO drugs, especially in “cold tumors”
- **Systemic activation of CD40 via mAbs** has been hampered by **significant toxicities,** therefore **limiting their potential of reaching a therapeutically active dose**

Solution: MP0317 – FAP-dependent tumor-localized CD40 activation





- **FAP is a validated tumor target** overexpressed in at least 28 different cancer types and its expression is not downregulated during disease progression
- **MP0317** is designed to bind tumor-localized FAP and induce CD40-mediated **activation of immune cells in the tumor**, thereby overcoming systemic toxicity and allowing a **wider therapeutic dosing range**

DC, dendritic cell; FAP, fibroblast activation protein; HSA, human serum albumin; MΦ, macrophage; mAb, monoclonal antibody; IO: immuno-oncology.

MP0317 Leads to Remodeling of Tumor Microenvironment

PRIOR TO TREATMENT



MP0317

DC infiltration

CYCLE 2 DAY 8



High DC infiltration in FAP-positive tumor area in presence of MP0317

Summary of MP0317 Phase 1 Study

- **46 patients treated** in 9 cohorts
- **Favorable safety profile** across all tested dose cohorts up to highest planned dose (10 mg/kg)
- **Clinical evidence** of tumor-localized CD40 pathway and immune cell activation, leading to **tumor microenvironment remodeling**

Gomez-Roca et al, SITC 2023 poster presentation

Tumor biopsy of a patient with GIST in Cohort 5b (Q1W); biopsy location: peritoneum.
DC, dendritic cell; FAP, fibroblast activation protein; GIST, gastrointestinal stromal tumor.

MP0317 Phase 2 Combo Study in Advanced Biliary Tract Cancer

Study Objective (NCT07036380)

- Investigator-initiated, randomized, multicenter study to assess the clinical benefit (safety and efficacy) of MP0317 combined with standard of care (SoC) in 1st line advanced biliary tract cancer (cholangiocarcinoma)

Background

- **Why Cholangiocarcioma: high FAP expression, immune suppressive TME**
- Hypothesis: MP0317 to enable SOC via TME remodeling
- **SoC benchmark** (durvalumab (anti-PD-L1), plus gemcitabine/cisplatin): **12-month PFS rate ~24%**, median OS 12.8 months[1]

Outlook & Objective

- Increase duration of response (**12-month PFS rate ~36%**)
- Open label study & interim analysis by YE 2027

Ph2 Study Recruiting

Study design



MP0317 given Q3W, 5 cycle. SoC given Q3W for 8 cycles, followed by Durvalumab only for maintenance every 4 weeks until progression. Simon two-stage design; futility analysis n=20. [1]Do-Youn Oh et al, NEJM Evid 2022;1(8); DOI: 10.1056/EVIDoa2200015 (TOPAZ-1 study).
PFS, progression-free survival; OS, overall survival; TME, tumor microenvironment; YE, year-end.

MP0533

Tetra-specific, Mutation-agnostic T-cell Engager for AML

- Phase 1/2a ongoing and validating dose level
- Decisional data in H1 2026 to inform next steps

MP0533: A Tetra-specific TCE for Consolidation Therapy in AML

Half-life Extension
- 2 x HSA DARPins
- ~2-day half-life

CD33 x CD123 x CD70
- Broadest coverage of AML heterogeneity (3 antigens) addressing poly-clonality
- Selectivity for AML vs healthy cells

Anti-CD3
- T cell engager (TCE)
- Mutation agnostic AML killing mechanism



MP0533 eradicates all escaping AML cells



AML heterogeneity enables clones to evade SoC



DARPin, designed ankyrin repeat protein; HSA, human serum albumin; SoC, standard of care; TCE, T cell engager.

Encouraging Clinical Responses in Patients with Low Disease Burden

Intermediate densification (DR 8)

3 responders (of 8 patients), manageable safety





Further Densification (DR 9*)

1 responder (of 7 patients), manageable safety





THE PREFERRED PATIENT FOR MP0533 TREATMENT

*DR 9 Included pre-treatment with obinutuzumab
Bories et al. ASH 2025 Poster Presentation
Data cut-off: 01 Sept 2025

CR, complete response; CRh/CRi, CR with partial/incomplete hematologic recovery; DR, dose regimen; ELN, European LeukemiaNet; MDS, myelodysplastic syndrome; MLFS, morphologic leukemia-free state.

Mutation-agnostic AML-cell Killing in Patients



Further Densification (DR 9*)

1 responder (of 7 patients), manageable safety





*DR 9 Included pre-treatment with obinutuzumab
Bories et al. ASH 2025 Poster Presentation
Data cut-off: 01 Sept 2025

BMA, bone marrow aspirate; CR, complete response; CRh/CRi, CR with partial/incomplete hematologic recovery; DR, dose regimen; ELN, European LeukemiaNet; MDS, myelodysplastic syndrome; MLFS, morphologic leukemia-free state.

Planned Segments for MP0533 Development – IIT

Front-line AML – suboptimal response



"Maximize market value (of combo)"

- Company-sponsored
- ADAPT, HOVON

R/R AML – relapse



"Fast to market"

- Company-sponsored
- INTERCEPT

Aza, azacitidine; IIT, investigator-initiated trial; RR, response rate; R/R, relapsed/refractory; Ven, venetoclax.

Switch-DARPin Platform

Next-generation T cell engagers

CD3 Switch-DARPin for Next-Gen TCEs with Enhanced Function

Tackling current limitations of TCEs in solid tumors

OFF **CD3 DARPin masked by 2-in-1 Switch in absence of TAAs**



No immune cell engagement

- **TCE is silent and inactive in circulation**

ON **Binding to TAAs releases CD3 Switch-DARPin**



Immune cell-mediated killing

- **TCE is activated to kill the tumor cell**
- **TCE is co-stimulated (no exhaustion)**

Next update on CD3 Switch TCE at **AACR 2026**

TAA, tumor associated antigen; TCE, T cell engager.

MSLN x EpCAM x CD2 x CD3 Switch-DARPin Enables “AND-Gate” for Preferential Killing of Double vs Single TAA Expressing Cells











Bianchi et al, AACR 2025

EpCAM; epithelial cellular adhesion molecule; MSLN, mesothelin.

CD3 Switch-DARPin with CD2 Co-Stimulation Induces Tumor Regression

Antitumor activity in OVCAR-3 xenograft model



Safety of CD2/CD3 Switch: *in vivo* cytokine release

Serum cytokines in blood taken at 2 h post first injection were analyzed using MSD U-plex system.



- Masking of CD3 allows the safe use of strong CD3 and co-stimulation binders in one molecule
- Also confirmed in human whole blood cytokine release assay

Robinson et al, SITC 2024
Bianchi et al, AACR 2025

TNF, tumor necrosis factor; IL-6, interleukin-6;
PBS, phosphate buffered saline; PBMCs, peripheral blood mononuclear cells.

CD2 Co-stimulation Enables Sustained T Cell Function

Superior T cell proliferation profile



Higher cytotoxic activity



Setup of repetitive T cell stimulation assay:



Bianchi et al, SITC 2025

After 3 rounds, T cells were co-cultured with labeled Caov-3 cells and DARPins for 48h in an IncuCyte to measure killing.

Fc-Switch-DARPin Supports Q2W–Q3W Dosing Schedule in Clinic





Parameter	Fc
MW (kDa)	115
Mouse Cmax (nM)	76.5
Mouse HL (h)	~50–80h
Scaled human HL (weeks)	2–3(1)

(1) Scaling based on known HL of human IgG Fc in mice, which is of 1-2 days (as experimentally measured for the Fc) vs 21 days in human

Bianchi et al, SITC 2025

PK characteristics of Switch-DARPin in female wild-type BALB/c mice following single i.v. bolus injection of 1 mg/kg. Results represent two groups with n=3 mice per time point (mean, SD). Concentrations were measured by sandwich ELISA. PK, pharmacokinetics; MW, molecular weight; HLE, half-life extension.